Answer
Oedema or fluid retention is very common (at least 1 in 10) during bosentan treatment, reported in 13.2% of bosentan-treated patients versus 10.9% receiving placebo in placebo-controlled studies.
Sources for this answer
- Bosentan Milpharm 125 mg film-coated tabletsAurobindo Pharma - Milpharm Ltd. · emc · SmPC §4.8 Undesirable effects · Version 11Document updated
Sources checked